Binimetinib (Standard)
- Availability: 24/48H Stock Items & 2 to 6 Weeks non Stock Items.
- Dry Ice Shipment: No


Binimetinib (Standard)
Description:
Binimetinib (Standard) is the analytical standard of Binimetinib. This product is intended for research and analytical applications. Binimetinib (MEK162) is an oral and selective MEK1/2 inhibitor. Binimetinib (MEK162) inhibits MEK with an IC50 of 12 nM.Product Name Alternative:
MEK162 (Standard) ; ARRY-162 (Standard) ; ARRY-438162 (Standard)UNSPSC:
12352005Hazard Statement:
H411Target:
Autophagy; MEK; Reference StandardsType:
Reference StandardsRelated Pathways:
Autophagy; MAPK/ERK Pathway; OthersField of Research:
CancerAssay Protocol:
https://www.medchemexpress.com/binimetinib-standard.htmlSmiles:
BrC1=CC=C(C(F)=C1)NC2=C(C3=C(C=C2C(NOCCO)=O)N(C=N3)C)FMolecular Formula:
C17H15BrF2N4O3Molecular Weight:
441.23Precautions:
P273-P391-P501References & Citations:
[1]J Pheneger, et al. 2006, ACR Annual Scientific Meeting. Abst 794.|[2]Serra V, et al. RSK3/4 mediate resistance to PI3K pathway inhibitors in breast cancer. J Clin Invest, 2013, 123 (6), 2551-2563.|[3]Kiessling MK, et al. Mutant HRAS as novel target for MEK and mTOR inhibitors. Oncotarget. 2015 Dec 8;6 (39) :42183-96.|[4]Cheng H, et al. PIK3CA (H1047R) - and Her2-initiated mammary tumors escape PI3K dependency by compensatory activation of MEK-ERK signaling. Oncogene. 2016 Jun 9;35 (23) :2961-70.|[5]Seip K, et al. Fibroblast-induced switching to the mesenchymal-like phenotype and PI3K/mTOR signaling protects melanoma cells from BRAF inhibitors. Oncotarget. 2016 Apr 12;7 (15) :19997-20015.Shipping Conditions:
Room temperatureScientific Category:
Reference StandardsCAS Number:
[606143-89-9]
